This article presents a quarterly round-up of the latest trends in the pharmaceutical industry regarding immuno-oncology. It provides an overview of recent developments in immuno-oncology-related deals, talent acquisition, and patent filings within the pharmaceutical industry.

Diverse applications of immuno-oncology in pharmaceutical industry

Pharma companies in the field of immuno-oncology are leveraging new technologies and applications to innovate and improve their businesses. One such technology is the use of alternating polarity magnetic fields to treat cancer cells. ASHA MEDICAL, INC. has patented a system that includes an alternating polarity magnetic field generator and electromagnetic coil to apply a magnetic field to the target body area, inhibiting the growth of cancer cells. This treatment can be co-administered with anti-cancer drugs for enhanced effectiveness.

Another patent focuses on genome editing using histone deacetylase inhibitors and Cas9 ribonucleoprotein. By treating target cells with these inhibitors, the chromatin is decondensed, allowing for site-specific genome editing. This technology has the potential to revolutionize gene editing therapies.

Eltrombopag, a drug used to treat certain blood disorders, has been discovered to inhibit BAX-mediated cell death. The Children's Hospital at Montefiore has patented the use of eltrombopag as a potent binder to the BAX trigger site, effectively inhibiting BAX activity. This finding opens up new possibilities for treating BAX-mediated disorders.

Nanoparticles are being explored as carriers for HPV-derived immunogenic fragments. These nanoparticles can be used for medical purposes such as immunoprophylaxis or immunotherapy. The development of a vaccine containing these nanoparticles could lead to more effective prevention and treatment of HPV-related diseases.

Lastly, antibodies targeting the cellular efflux pump ABCC1 have been patented. These antibodies can be used for detecting ABCC1 expression in tumor cells and inhibiting its function. Bispecific antibodies that bind to both ABCC1 and tumor-associated antigens are also disclosed, offering a potential dual-targeting approach for cancer treatment.

Overall, these patents highlight the ongoing efforts of pharma companies to develop innovative technologies and applications in the field of immuno-oncology. By leveraging these advancements, the acquirer of these patents stands to benefit from improved treatment options and potential breakthroughs in cancer therapy.

Strategic deal trends in immuno-oncology in pharmaceutical industry

Pharmaceutical companies are not only focusing on innovation to enhance their patent portfolios but are also making strategic investments in immuno-oncology. These investments aim to secure lucrative deals with partners and position themselves at the forefront of industry advancements. Some of the recent deals underscore the importance of immuno-oncology in the pharmaceutical industry.

In Q3 2023, the number of immuno-oncology-related deals in the pharmaceutical industry declined by 47% compared with Q3 2022. On a quarterly basis, there was 49% drop in the number of deals in Q3 2023 compared with the previous quarter.

Impact on hiring

In terms of new job posting, in Q3 2023, the pharmaceutical industry experienced a 27% drop compared with the previous quarter. On an annual basis, job postings also declined by 70%. Notably, management occupations, with a share of 33%, emerged as the top immuno-oncology-related job roles within the pharmaceutical industry in Q3 2023, with new job postings drop by 24% quarter-on-quarter. Life, physical, and social science occupations came in second with a share of 22% in Q3 2023, with new job postings dropping by 14% over the previous quarter. The other prominent immuno-oncology roles include sales and related occupations with a 14% share in Q3 2023, and healthcare practitioners and technical occupations with a 5% share of new job postings.

Merck, Bristol-Myers Squibb, Gilead Sciences, AstraZeneca, and Dendreon Pharmaceuticals are among the top companies leading in immuno-oncology hiring within the pharmaceutical industry.

Countries driving adoption of immuno-oncology in pharmaceutical industry

The US is the leading country in immuno-oncology adoption within the pharmaceutical industry, boasting the highest number of immuno-oncology-related patents, jobs, and deals. Meanwhile, China, the UK, Australia and Japan also maintain significant positions in immuno-oncology adoption within the pharmaceutical industry.

In conclusion, the pharmaceutical industry's immuno-oncology landscape showcases a surge in innovative patents, strategic deals, and a shifting job market. With companies like Merck and AstraZeneca leading in immuno-oncology hiring, the dynamic interplay of advancements positions stakeholders to harness the potential of groundbreaking technologies for enhanced cancer therapies.

To further understand GlobalData's analysis on immuno-oncology in the pharmaceutical industry, buy the report here.

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData patent analytics tracks patent filings and grants across companies and themes. Proprietary databases on deals and job analytics are used to respectively monitor global deal activity and uncover insights from daily job postings to identify trends, company activities, and industry dynamics across different sectors globally.

Immuno-oncology in the pharmaceutical industry: analyzing innovation, investment and hiring trends

Smarter leaders trust GlobalData